Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
BioPharma Dive
To analysts, the drug s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
pharminent
July 22, 2026 (Last updated: July 27, 2026)
BioPharma Dive
To analysts, the drug s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
